TD Cowen lowered the firm’s price target on Jazz Pharmaceuticals to $200 from $225 and keeps a Buy rating on the shares. The firm said Q1 revenue came in below expectations affected by patient reimbursement dynamics for patients transitioning from Xyrem to Xywav in the quarter though patient adds in IH continued to grow in line.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
- Baird starts Praxis Precision at Outperform on ulixacaltamide’s potential
- JAZZ Earnings this Week: How Will it Perform?
- Jazz completes rolling submission of BLA for zanidatamab antibody
- Jazz Pharmaceuticals price target raised to $188 from $171 at Piper Sandler